| Supplier |
CD BioSciences |
| Product # |
AMA-0299 |
| Pricing |
100 µL, Inquire
|
| Product Category |
Antibodies
|
| Application |
WB, IP
|
| Product Usage Information Dilution |
Western Blotting (1:1000); Immunoprecipitation (1:50)
|
| Reactivity |
Human
|
| Gene ID |
595
|
| UniProt ID |
|
| MW (Target) |
36 kDa
|
| Storage |
Store at -20°C. Do not aliquot the antibody.
|
| Purification |
Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of cyclin D1. Antibodies are purified by protein A and peptide affinity chromatography.
|
| Background |
Activity of the cyclin-dependent kinases CDK4 and CDK6 is regulated by T-loop phosphorylation, by the abundance of their cyclin partners (the D-type cyclins), and by association with CDK inhibitors of the Cip/Kip or INK family of proteins. The inactive ternary complex of cyclin D/CDK4 and p27 Kip1 requires extracellular mitogenic stimuli for the release and degradation of p27 concomitant with a rise in cyclin D levels to affect progression through the restriction point and Rb-dependent entry into S-phase. The active complex of cyclin D/CDK4 targets the retinoblastoma protein for phosphorylation, allowing the release of E2F transcription factors that activate G1/S-phase gene expression. Levels of cyclin D protein drop upon withdrawal of growth factors through downregulation of protein expression and phosphorylation-dependent degradation.
|